Navigation Links
Gene therapy reversed heart damage in heart failure
Date:12/29/2008

(PHILADELPHIA) Long-term gene therapy resulted in improved cardiac function and reversed deterioration of the heart in rats with heart failure, according to a recent study conducted by researchers at Thomas Jefferson University's Center for Translational Medicine. The study was published online in Circulation.

The rats were treated with a gene that generates a peptide called ARKct, which was administered to hearts in combination with recombinant-adeno-associated virus serotype 6 (rAAV6). ARKct works by inhibiting the activation of G protein-coupled receptor kinase 2 (GRK2).

GRK2 is a kinase that is increased in heart failure myocardium. Enhanced GRK enzymatic activity contributes to the deterioration of the heart in heart failure, according to Walter J. Koch, Ph.D., the W.W. Smith Professor of Medicine and the director of the Center for Translational Medicine at Jefferson Medical College of Thomas Jefferson University. Dr. Koch's research team carried out the study, which was led by Giuseppe Rengo, M.D., a post-doctoral fellow.

"The theory is that by inhibiting this kinase, the heart will recover partially due to reversal of the desensitization of the -adrenergic receptors," Dr. Koch said. "The expression of ARKct leads to a negative neurohormonal feedback that prevents the heart from continuing on the downward slope during heart failure. This was one novel finding of the study."

Dr. Koch and his colleagues used five groups of rats in their study. Two groups received rAAV6 with the ARKct peptide, two groups received rAAV6 with green fluorescent protein (GFP), and the last group received a saline treatment. One of the ARKct groups and one of the GFP groups also received the beta blocker metoprolol concurrently.

Twelve weeks after receiving the treatment, the rats who received the ARKct had a significantly increased left ventricular ejection fraction. The treatment also reversed the left ventricular deterioration and normalized the neurohormonal status. Dr. Koch said that targeting the GRK2 enzyme with ARKct was sufficient to reverse heart failure even without concomitant metoprolol.

The rats that received GFP or saline alone experienced more deterioration of cardiac function during the course of the study. This deterioration was prevented, but not reversed, with the concomitant metoprolol.

"Our data show that beta blockers and the ARKct peptide are compatible and can be given together," Dr. Koch said. "Although beta blockers are effective at stopping the downward progression of the disease, they do not reverse the damage already done. That is where the ARKct gene therapy comes in."

In future trials in humans, the ARKct peptide will be administered with beta blockers, which are the standard treatment. However, Dr. Koch said that if a pharmaceutical inhibitor can be developed, then a new class of drugs to treat heart failure could possibly even replace beta blockers.


'/>"/>

Contact: Emily Shafer
emily.shafer@jefferson.edu
215-955-5291
Thomas Jefferson University
Source:Eurekalert

Related biology news :

1. Leeds research points to new therapy for hepatitis C treatment
2. UC Davis researchers exploring gene therapy to fight AIDS
3. Gene therapy corrects sickle cell disease in laboratory study
4. Medicare coding for maggots and maggot therapy
5. Scientist clears hurdles for muscular dystrophy therapy
6. Researchers at UH explore use of fat cells as heart attack therapy
7. How eating fruit and vegetables can improve cancer patients response to chemotherapy
8. Gene therapy restores vision to mice with retinal degeneration
9. Researchers identify promising gene target for neuroblastoma therapy
10. On the trail of a targeted therapy for blood cancers
11. Breast cancer cells recycle to escape death by hormonal therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/14/2017)... -- Wake Forest Baptist Medical Center today announced Julie Ann Freischlag, ... (CEO). Freischlag joins the medical center on May 1 ... who last year announced that he would transition to ... it since 2008.   As CEO, Freischlag ... academic health system, which includes Wake Forest School of ...
(Date:2/10/2017)... DUBLIN , Feb 10, 2017 ... PharmaBiotech,s new report "Personalized Medicine - Scientific and Commercial ... ... in personalized medicine. Diagnosis is integrated with therapy for selection ... emphasis on early detection and prevention of disease in modern ...
(Date:2/8/2017)... 7, 2017  Aware, Inc. (NASDAQ: AWRE ), ... financial results for its quarter and year ended December 31, ... 2016 was $3.9 million compared to $6.9 million in the ... of 2016 was $0.6 million compared to $2.6 million in ... quarter of 2016 was $0.5 million, or $0.02 per diluted ...
Breaking Biology News(10 mins):
(Date:2/23/2017)... ... February 23, 2017 , ... ... annual Inventors Recognition Reception at Purdue Research Park of West Lafayette, ... in recognition of outstanding contributions to, and success with, commercializing discoveries from Purdue ...
(Date:2/23/2017)... 2017  Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company ... announced that Linda Marbán, Ph.D, president and chief executive officer, ... Cowen and Company 37th Annual Health Care ... Boston, MA 29th Annual ... (12:00 pm ET) Dana Point, CA ...
(Date:2/23/2017)... BELLINGHAM, Washington, USA, and CARDIFF, UK (PRWEB) , ... ... ... SPIE, the international society for optics and photonics , have been named Fellows ... each individual’s significant scientific and technical contributions in the multidisciplinary fields of optics, ...
(Date:2/22/2017)... Santa Clara, CA (PRWEB) , ... February 22, 2017 , ... ... is hosting a free AFM Luncheon for all SPIE attendees ... San Jose, CA, just one block from the San Jose Convention Center. The ...
Breaking Biology Technology: